减肥药市场的“双王之争”突现重大变化。诺和诺德周五表示,其实验性下一代肥胖药物Cagrisema在一项晚期试验中帮助超重患者减重22.7%,这低于其此前预期的25%。受此影响,诺和诺德盘前股价一度暴跌超20%,其直接竞争对手礼来盘前股价则大涨。截至记者发稿,诺和诺德盘前股价依然暴跌17.83%,礼来盘前股价则上涨5.45%。作为糖尿病和肥胖症治疗领域的领导者,多年来,诺和诺德凭借其相关创新产品占据...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.